27 April 2016 - The European Commission has approved Eli Lilly’s biologic Taltz as a new treatment for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Taltz (ixekizumab) is an antibody specifically designed to target the cytokine interleukin IL-17A, a protein that plays a role in driving underlying inflammation in psoriasis.

Its approval comes on the back of data from seven clinical trials, including three pivotal double-blinded multi-centre Phase III studies (UNCOVER), which involved more than 3,800 psoriasis patients from 21 countries.

According to the data, for patients treated with the monoclonal antibody either every four weeks or every two weeks, between 78 percent and 90 percent achieved at least a 75% reduction in the Psoriasis Area and Severity Index score at 12 weeks.

For more details, go to: http://www.pharmatimes.com/Article/16-04-27/Lilly_s_Taltz_cleared_in_the_EU_for_plaque_psoriasis.aspx